Skip to content
DraconiticResearch
Search Sources API
203,952 studies31 sourcesUpdated 37 min ago
Peer-reviewedCC BY 4.0JAMA Internal Medicine

Risk of Shoulder Injury Related to Vaccine Administration for COVID-19 and Influenza Vaccinations

  • Chengyi Zheng1
  • Lei Qian1
  • Lina S. Sy1
  • Gabriella V. Goodwin1
  • Meiyu Yeh1
  • Ronald A. Navarro2,3
  • Dawn T. Asamura1
  • Denison S. Ryan1
  • Jonathan Duffy4
  • Jennifer C. Nelson5
  • Bruno J. Lewin3,6
  • Hung Fu Tseng1,3
6 affiliations
  1. 1Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena
  2. 2Department of Orthopedic Surgery, Kaiser Permanente South Bay Medical Center, Harbor City, California
  3. 3Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California
  4. 4Immunization Safety Office, Centers for Disease Control and Prevention, Atlanta, Georgia
  5. 5Kaiser Permanente Washington Health Research Institute, Seattle
  6. 6Department of Family Medicine, Kaiser Permanente Los Angeles Medical Center, Los Angeles, California
Read full textDOICite

Abstract

Importance: The National Academies of Sciences, Engineering, and Medicine identified a critical evidence gap regarding the risk of shoulder injury related to vaccine administration (SIRVA) after COVID-19 vaccination.

Objective: To compare the risk of SIRVA after COVID-19 vs influenza vaccinations in adults.

Design, Setting, and Participants: This population-based cohort study included individuals aged at least 18 years who received a COVID-19 or influenza vaccination administered via intramuscular deltoid injection between August 1, 2023, and April 30, 2024, at Kaiser Permanente Southern California. Data were analyzed from June 2024 to September 2026.

Exposure: Receipt of COVID-19 vaccination or influenza vaccination.

Main Outcomes and Measures: The primary outcome was incident SIRVA, defined as shoulder symptoms beginning at or before 7 days and persisting more than 30 days after vaccination, identified using a validated natural language processing algorithm. Incidences were calculated per 10 000 vaccinations. Adjusted relative risks (RRs), risk differences, and 95% CIs were estimated using robust Poisson regression with inverse probability of treatment weighting.

Results: A total of 1 366 362 individuals (mean [SD] age at vaccination, 58.4 [18.2] years; 782 994 female [57.3%]) across 1 901 588 vaccinations were included (1 076 609 vaccinations [56.7%] were administered to females). Among 1 830 636 vaccinations in the primary analysis, 252 SIRVA cases were identified as follows: 110 cases (0.018%) after 596 614 COVID-19 vaccinations and 142 cases (0.012%) after 1 234 022 influenza vaccinations. An additional 13 SIRVA cases (0.018%) were identified among 70 952 simultaneous COVID-19 and influenza vaccinations. Most COVID-19 vaccines were Pfizer-BioNTech messenger RNA (667 455 of 667 566 [99.98%]), and influenza vaccines were predominantly standard-dose (866 530 of 1 304 974 [66.40%]) or high-dose (438 183 of 1 304 974 [33.58%]) inactivated quadrivalent formulations. SIRVA incidence was higher after COVID-19 than influenza vaccination, at an incidence of 1.84 (95% CI, 1.53-2.22) vs 1.15 (95% CI, 0.98-1.36) per 10 000 vaccinations, corresponding to an adjusted absolute increase of 0.67 cases (95% CI, 0.15-1.19) per 10 000 vaccinations (adjusted RR, 1.63; 95% CI, 1.16-2.28). Among adults 65 years or older, SIRVA incidence was 2.11 (95% CI, 1.67-2.67) per 10 000 for COVID-19 vaccination and 1.63 (95% CI, 1.28-2.07) per 10 000 for high-dose influenza vaccination (adjusted RR, 1.41; 95% CI, 0.92-2.15).

Conclusions and Relevance: Results of this cohort study suggest that although SIRVA was rarely associated with both vaccines, COVID-19 vaccination was associated with approximately 7 additional cases per 100 000 vaccinations compared with influenza vaccination. Among adults aged 65 years or older, SIRVA risk did not differ significantly between COVID-19 and high-dose influenza vaccination. The small absolute risk of SIRVA should be considered alongside the established benefits of COVID-19 and influenza vaccination in preventing severe disease and hospitalization.

Related

  1. Cutaneous Events After Recombinant Zoster Vaccination and Shoulder Injury Related to Zoster Vaccine Administration: A Narrative Review
    Carlo Ciccullo, Arturo Ciccullo, Sonia Farah +8
    Journal of Clinical MedicinePeer-reviewedCC BY 4.0Full textEpidemiology & public healthCrossrefEurope PMC
  2. Establishing a human co-infection challenge study of Streptococcus pneumoniae (Spn) and live attenuated influenza vaccine (LAIV) in older healthy adults: E xploring C o-infection with L ive Attenuated I nfluenza Vaccine and P neumococcu S in healthy old E r adults (ECLIPSE), a UK-based single-centre, single-blind randomised controlled trial
    Rebecca I Jackson, Oisin Hennigan, Karen Kelleher +20
    BMJ OpenPeer-reviewedCC BY 4.0Full textEpidemiology & public healthCrossref
  3. An LLM enabled real-time estimation of seasonal influenza vaccine effectiveness from social media data
    M. J. Pavia, I. F. Amaro, D. Xu +2
    medRxivPreprintCC BY-NC-NDFull textEpidemiology & public healthmedRxiv
  4. A Bayesian Re-analysis of the GALFLU Trial of High-Dose vs Standard-Dose Influenza Vaccine Against Hospitalization Outcomes
    Jacobo Pardo-Seco, Carmen Rodriguez-Tenreiro-Sánchez, Iago Giné-Vázquez +20
    Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of AmericaPeer-reviewedCC BY-NC-ND 4.0Full textEpidemiology & public healthPMC
  5. Protective effect of influenza vaccine in Brazilian patients hospitalised for severe acute respiratory infection, 2023-2025
    E. Kupek
    medRxivPreprintCC BYFull textEpidemiology & public healthmedRxiv

Cite

BibTeXRIS
BibTeX
@article{zheng2026risk,
  title = {{Risk of Shoulder Injury Related to Vaccine Administration for COVID-19 and Influenza Vaccinations}},
  author = {Chengyi Zheng and Lei Qian and Lina S. Sy and Gabriella V. Goodwin and Meiyu Yeh and Ronald A. Navarro and Dawn T. Asamura and Denison S. Ryan and Jonathan Duffy and Jennifer C. Nelson and Bruno J. Lewin and Hung Fu Tseng},
  journal = {JAMA Internal Medicine},
  year = {2026},
  month = nov,
  doi = {10.1001/jamainternmed.2026.5899},
  url = {https://doi.org/10.1001/jamainternmed.2026.5899},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Risk of Shoulder Injury Related to Vaccine Administration for COVID-19 and Influenza Vaccinations
AU  - Chengyi Zheng
AU  - Lei Qian
AU  - Lina S. Sy
AU  - Gabriella V. Goodwin
AU  - Meiyu Yeh
AU  - Ronald A. Navarro
AU  - Dawn T. Asamura
AU  - Denison S. Ryan
AU  - Jonathan Duffy
AU  - Jennifer C. Nelson
AU  - Bruno J. Lewin
AU  - Hung Fu Tseng
PY  - 2026
DA  - 2026/11/04
JO  - JAMA Internal Medicine
DO  - 10.1001/jamainternmed.2026.5899
UR  - https://doi.org/10.1001/jamainternmed.2026.5899
AB  - Importance: The National Academies of Sciences, Engineering, and Medicine identified a critical evidence gap regarding the risk of shoulder injury related to vaccine administration (SIRVA) after COVID-19 vaccination.  Objective: To compare the risk of SIRVA after COVID-19 vs influenza vaccinations in adults.  Design, Setting, and Participants: This population-based cohort study included individuals aged at least 18 years who received a COVID-19 or influenza vaccination administered via intramuscular deltoid injection between August 1, 2023, and April 30, 2024, at Kaiser Permanente Southern California. Data were analyzed from June 2024 to September 2026.  Exposure: Receipt of COVID-19 vaccination or influenza vaccination.  Main Outcomes and Measures: The primary outcome was incident SIRVA, defined as shoulder symptoms beginning at or before 7 days and persisting more than 30 days after vaccination, identified using a validated natural language processing algorithm. Incidences were calculated per 10 000 vaccinations. Adjusted relative risks (RRs), risk differences, and 95% CIs were estimated using robust Poisson regression with inverse probability of treatment weighting.  Results: A total of 1 366 362 individuals (mean [SD] age at vaccination, 58.4 [18.2] years; 782 994 female [57.3%]) across 1 901 588 vaccinations were included (1 076 609 vaccinations [56.7%] were administered to females). Among 1 830 636 vaccinations in the primary analysis, 252 SIRVA cases were identified as follows: 110 cases (0.018%) after 596 614 COVID-19 vaccinations and 142 cases (0.012%) after 1 234 022 influenza vaccinations. An additional 13 SIRVA cases (0.018%) were identified among 70 952 simultaneous COVID-19 and influenza vaccinations. Most COVID-19 vaccines were Pfizer-BioNTech messenger RNA (667 455 of 667 566 [99.98%]), and influenza vaccines were predominantly standard-dose (866 530 of 1 304 974 [66.40%]) or high-dose (438 183 of 1 304 974 [33.58%]) inactivated quadrivalent formulations. SIRVA incidence was higher after COVID-19 than influenza vaccination, at an incidence of 1.84 (95% CI, 1.53-2.22) vs 1.15 (95% CI, 0.98-1.36) per 10 000 vaccinations, corresponding to an adjusted absolute increase of 0.67 cases (95% CI, 0.15-1.19) per 10 000 vaccinations (adjusted RR, 1.63; 95% CI, 1.16-2.28). Among adults 65 years or older, SIRVA incidence was 2.11 (95% CI, 1.67-2.67) per 10 000 for COVID-19 vaccination and 1.63 (95% CI, 1.28-2.07) per 10 000 for high-dose influenza vaccination (adjusted RR, 1.41; 95% CI, 0.92-2.15).  Conclusions and Relevance: Results of this cohort study suggest that although SIRVA was rarely associated with both vaccines, COVID-19 vaccination was associated with approximately 7 additional cases per 100 000 vaccinations compared with influenza vaccination. Among adults aged 65 years or older, SIRVA risk did not differ significantly between COVID-19 and high-dose influenza vaccination. The small absolute risk of SIRVA should be considered alongside the established benefits of COVID-19 and influenza vaccination in preventing severe disease and hospitalization.
SN  - 2168-6106
SN  - 2168-6114
ER  -